Drugs / ICT-107
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01280552 | Jan 2011 → Dec 2013 | glioblastoma | Precision Life Sciences Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02546102 | Dec 2024 → Dec 2025 | glioblastoma | Precision Life Sciences Group | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICT-107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01280552 ↗ |
| Modality | Cell therapy | “The patient's own WBC/DC that have been exposed to the tumor antigens will then be given back to the patient as a vaccine over several months.” NCT01280552 ↗ |
| Route | Other | “Patients will have the autologous DCs reinfused intradermally.” NCT01280552 ↗ |